ai
20/20 Biolabs
AIDX
NASDAQ $0.53
How predictable is 20/20 Biolabs's business?
Revenue is small and lumpy, tied to state firefighter grants and discrete account wins. FY2025 revenue was 2.05 million; 1H 2026 revenue was 1.08 million with guidance commentary citing expected benefits from grants, not contracted recurring revenue.
Serial testing could improve predictability long term if integrated into protocols and covered by payers after 2028, but OneTest remains an LDT without FDA authorization today, and broader LDT oversight remains unsettled following vacatur of the 2024 final rule.
Competitive readouts like NHS‑Galleri’s mixed results highlight the evidentiary hurdle for population screening.
Read the full report on 20/20 Biolabs and explore the other sections
Overview of 20/20 Biolabs
Does 20/20 Biolabs have a strong competitive moat?
Does 20/20 Biolabs have pricing power in its industry?
How predictable is 20/20 Biolabs's business?
Is 20/20 Biolabs financially strong?
How effective is 20/20 Biolabs's capital allocation strategy?
Does 20/20 Biolabs have high-quality management?
What is the fair value of 20/20 Biolabs stock?